Skip to content
    Clinical Trials

    Adjuvant mFOLFOXIRI and ctDNA Dynamics Following Resection of Oligometastatic Colorectal Cancer

    Kataoka et alBJS open

    Adjuvant mFOLFOXIRI and ctDNA Dynamics Following Resection of Oligometastatic Colorectal Cancer
    In the multicentre non-randomized phase II FANTASTIC study, researchers evaluated the feasibility and efficacy of adjuvant modified FOLFOXIRI (irinotecan, oxaliplatin, L-leucovorin, and 5-fluorouracil) alongside the prognostic utility of circulating tumour DNA (ctDNA) in patients with oligometastatic colorectal cancer undergoing complete metastasectomy. Between October 2020 and January 2024, 73 of 83 registered patients were enrolled; 39 received adjuvant mFOLFOXIRI (eight cycles followed by four cycles of 5-FU/L-LV) and 34 received standard of care (CAPOX, 5-FU, or observation).
    The primary endpoint of completing eight cycles of mFOLFOXIRI in the target cohort was achieved with a 74% completion rate (80% CI 63% to 83%; P < 0.001). Compared with standard of care, mFOLFOXIRI improved recurrence-free survival in the overall population (HR 0.44; P = 0.012), accompanied by a trend toward benefit among ctDNA-positive patients that was not observed in ctDNA-negative patients. Postoperative ctDNA positivity assessed via a tumour-informed assay at 28 days and 7 months predicted significantly inferior recurrence-free survival across both arms (28-day HR 7.27 for mFOLFOXIRI and 7.17 for standard of care; 7-month HR 3.96 and 4.38, respectively). On multivariate analysis, ctDNA positivity, RAS mutation, metachronous metastases, and receipt of mFOLFOXIRI were identified as significant prognostic factors, supporting the feasibility, acceptable safety, and potential clinical utility of mFOLFOXIRI guided by ctDNA status.

    Key Takeaways

    • Adjuvant mFOLFOXIRI improved recurrence-free survival compared with standard of care across the study cohort (HR 0.44; P = 0.012), achieving a protocol completion rate of 74% (80% CI 63% to 83%; P < 0.001) for eight planned cycles.
    • Postoperative ctDNA positivity predicted significantly inferior recurrence-free survival in both mFOLFOXIRI and standard-of-care groups at 28 days (HR 7.27 and 7.17, respectively) and 7 months (HR 3.96 and 4.38, respectively), with ctDNA clearance observed in 33% versus 20% of patients.